KUALA LUMPUR, Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced it has reached a worldwide milestone by surpassing 10,000 patients having received the Optimizer system for the treatment of moderate HF.
According to a statement, this milestone highlights the benefit and importance of this therapy in helping patients live a full life with HF.
Impulse Dynamics Chief Executive Officer, Jason Spees said the company is committed to ongoing innovation in this important therapy that has such a clear clinical need worldwide.
‘We are also getting closer to significantly impacting the implantable cardioverter defibrillator (ICD) market with successful enrolment in our INTEGRA-D clinical trial on the CCM-D HF System, which is the first-of-its-kind technology, combining the lifesaving benefits of an ICD with HF symptom relief through CCM therapy in one device,’ he said.
Meanwhile, its Chief Technology Officer, David Prutchi who has worked o
n the development of therapy since its inception said: ‘We are deeply motivated by the patients who benefit from CCM therapy. Their progress inspires us to continuously enhance our technology, aiming to improve the lives of those suffering from heart failure.’
Cardiac contractility modulation (CCM) therapy is designed to significantly improve heart contraction, allowing more oxygen-rich blood to be pushed out through the body and is non-excitatory electrical pulses delivered by the implantable Optimizer device to improve heart contraction.
CCM is available in 44 countries, and the technology has continued to advance, based on the needs of patients and physicians.
The latest generation of the proprietary CCM technology is the Optimizer Smart Mini, which offers a rechargeable battery with 20-year battery life and a smaller size designed to make the implant procedure faster and easier for patients and physicians.
The Optimizer Smart Mini is a minimally invasive implantable device that treats patients experie
ncing moderate to severe congestive heart failure (CHF) symptoms even after appropriate medical treatment. The device operates by delivering precisely timed electric pulses called cardiac contractility modulation therapy.
As a result, patients receiving CCM therapy experience a higher quality of life by reducing CHF symptoms such as overwhelming shortness of breath and fatigue.
Source: BERNAMA News Agency
